TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00496873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoxan
Description: 600 mg/m\^2 on Day 1 of 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nipent
Description: 4 mg/m\^2 on Day 1 of 21 Day Cycle.
Study: NCT06449287

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: The diet intervention will start after all baseline testing is complete

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: The diet intervention will start after all baseline testing is complete
Study: NCT00496873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituxan
Description: 375 mg/m\^2 on Day 1 of 21 Day Cycle.
Study: NCT06449287

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: The diet intervention will start after all baseline testing is complete
Study: NCT04793672

Intervention type: OTHER
Intervention: Tongue images, coating on the tongue and clinical data of patients with malignant tumors and healthy people will be collected.
Description: Tongue images, coating on the tongue and clinical data of patients with malignant tumors and healthy people will be collected.
Study: NCT06449287

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood Draw
Description: Blood samples will be collected biweekly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood Draw
Description: Blood samples will be collected biweekly.
Study: NCT00536731

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort Turbuhaler
Description: Symbicort Turbuhaler® 80/4.5 μg 1 Inhalation Twice Daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort pMDI
Description: Symbicort®pMDI® 40/2.25 μg 2 Actuations Twice Daily
Study: NCT06449287

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood Draw
Description: Blood samples will be collected biweekly.
Study: NCT00536731

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pulmicort Turbuhaler
Description: Pulmicort®Turbuhaler® 100 μg 1 Inhalation Twice Daily
Study: NCT02402907

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate (CHG) cloth
Description: administration of a 2% CHG cloth at home on the night before and approximately 3 hours prior to cesarean delivery on the morning of the surgery.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cloth
Description: administration of a cloth with the placebo (commercial cleansing cloth) at home on the night before and approximately 3 hours prior to cesarean delivery on the morning of the surgery.
Study: NCT06449287

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ketone/Glucose Monitoring
Description: Hand-held glucometer will be used daily to monitor dietary intervention adherence.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ketone/Glucose Monitoring
Description: Hand-held glucometer will be used daily to monitor dietary intervention adherence.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ketone/Glucose Monitoring
Description: Hand-held glucometer will be used daily to monitor dietary intervention adherence.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body Composition
Description: DEXA Scanning will be done pre-, mid-, and post- intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body Composition
Description: DEXA Scanning will be done pre-, mid-, and post- intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Body Composition
Description: DEXA Scanning will be done pre-, mid-, and post- intervention.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Urine Analysis
Description: 24 hour urine collection will be done biweekly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Urine Analysis
Description: 24 hour urine collection will be done biweekly.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Urine Analysis
Description: 24 hour urine collection will be done biweekly.
Study: NCT01096771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ClinOleic 20%
Description: 96 hour continuous infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid 20%
Description: 96 hour continuous infusion.
Study: NCT06449287

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological Measures - ANAM
Description: The first cognitive assessment will be done via Automated Neuropsychological Assessment Metrics (ANAM). This cognitive battery is a library of computer-based tests of domains including attention, concentration, reaction time, memory, processing speed, decision-making, and executive function.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological Measures - ANAM
Description: The first cognitive assessment will be done via Automated Neuropsychological Assessment Metrics (ANAM). This cognitive battery is a library of computer-based tests of domains including attention, concentration, reaction time, memory, processing speed, decision-making, and executive function.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neuropsychological Measures - ANAM
Description: The first cognitive assessment will be done via Automated Neuropsychological Assessment Metrics (ANAM). This cognitive battery is a library of computer-based tests of domains including attention, concentration, reaction time, memory, processing speed, decision-making, and executive function.
Study: NCT01913132

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy with PICO (Smith & Nephew)
Description: Negative wound pressure therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy with PICO (Smith & Nephew)
Description: Negative wound pressure therapy
Study: NCT01613469

Intervention type: DRUG
Group type: OTHER
Intervention: 5FU/Leucovorin
Description: 450 mg/m2 of 5-FU plus 50 mg Leucovorin given in 3 cycles during radiation (one cycle is the administration every day for 3 consecutive days, a cycle is 21 days)followed by 450 mg/m2 of 5-FU plus 50 mg Leucovorin given in 3 cycles after completion of radiation.
Study: NCT04389463

Intervention type: OTHER
Intervention: No intervention
Description: No description

Intervention type: OTHER
Intervention: No intervention
Description: No description
Study: NCT04364048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction Durvalumab
Description: Induction durvalumab at 1500 mg intravenously (IV) will be given on Day 1 of a four week cycle for 1 cycle,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Concurrent chemoradiation will be with platinum-based chemotherapy (cisplatin or carboplatin, with etoposide, taxane, or pemetrexed) selected at the treating physician's discretion. The chemotherapy regimen used should be administered per institutional standards following the prescribing guidelines for each drug

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Treatment will be delivered using IMRT or 3DCRT using typically 6-10MV photons per institutional standards. 4D simulation and appropriate IGRT are encouraged. Radiation therapy must begin within one week of the first day of chemotherapy (or vice versa). Therapy will be 1.8-2 Gy per day; 5 days per week, excluding holidays per institutional standard as this is a standard of care regimen for this patient population. 54-66 Gy will be delivered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consolidation durvalumab
Description: Durvalumab at 1500 mg intravenously (IV) will be given on Day 1 of a four week cycle for 12 cycles
Study: NCT03091972

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation
Description: A pulmonary vein isolation procedure will be performed using radiofrequency ablation with contact force monitoring.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation
Description: A pulmonary vein isolation procedure will be performed using radiofrequency ablation with contact force monitoring.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contact force assisted left atrial linear ablation
Description: Left atrial linear ablation (Roof line and Anterior line) after pulmonary vein isolation during catheter ablation for persistent atrial fibrillation monitoring contact force.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: left atrial linear ablation without contact force monitoring
Description: Left atrial linear ablation (Roof line and Anterior line) after pulmonary vein isolation during catheter ablation for persistent atrial fibrillation without monitoring contact force.
Study: NCT01097798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliviador
Description: The study medication should be applied regimen of 8/8 hours over 2 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gelol
Description: The study medication should be applied regimen of 8/8 hours over 2 days.
Study: NCT02263131

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-YANG FLU Vaccine Prefilled Syringe INJ.
Description: IL-YANG FLU Vaccine Prefilled Syringe INJ.0.5mL or 0.25mL
Study: NCT01707212

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain management education
Description: Education about pain management during infant immunization

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: No pain management education
Description: Control - no education about pain management during infant immunization
Study: NCT01043523

Intervention type: DRUG
Intervention: Gadoxetic Acid Disodium (Eovist, BAY86-4873)
Description: Participants have received Primovist/Eovist for liver Magnetic Resonance Imaging (MRI) as part of their routine care at participating institutions and additional diagnostic information are identified retrospectively from institution records
Study: NCT02670551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00987480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan, fludarabine, & cyclophosphamide with immunosuppression with ATG and cyclosporine.
Description: There are three parts in this transplant study. 1) There will be a pre-transplant - preparation - period to see if patient qualifies for the transplant study. This will be done as an outpatient and lasts 2-4 weeks. Once this is completed, there will be 2) the transplant period itself, during which the patient will be admitted and will be an inpatient. This period usually last for 4-6 weeks. Following that, there will be a 3) post transplant period, during which the patient will be watched carefully and monitored in clinic as an out patient. The post transplant period lasts from three months to one year.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS device
Description: CD34+ T-cell depleted peripheral blood stem cell transplant
Study: NCT06221124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Belun Ring Pulse Oximeter
Description: Belun Ring Pulse Oximeter allows measurement and analysis of oximetry, pulse rate, photo-plethysmography (PPG), and accelerometer signals from the proximal phalanx of index finger. Sleep stage (bSTAGES) and respiratory event index (bAHI) are estimated.
Study: NCT03959150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Oral fluorouracil
Study: NCT00534430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Study: NCT00566657

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: riferminogene pecaplasmid
Description: Formulation: 5 ml glass vials containing 2,5 ml riferminogene pecaplasmid~Route: intramuscular (IM) injection of 2.5 mL in the ischemic leg to be treated

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for riferminogene pecaplasmid)
Description: Formulation: 5 ml glass vials containing 2,5 ml placebo~Route: IM injection of 2.5 mL in the ischemic leg to be treated
Study: NCT03789630

Intervention type: DEVICE
Intervention: Continuous physiology monitoring in ambulatory setting pre and post surgery
Description: This study will recruit 55 patients aged 21 to 80 years who will be undergoing total knee replacement surgery. All study participants undergoing total knee replacement surgery will be monitored using the wearable biosensor to continuously monitor physiology biomarkers. Participants will be followed for an estimated total of 39 days, beginning four days before surgery, the entire period during in-patient recovery (four to five days), and 30-days post-discharge at-home.
Study: NCT00397696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [123I] 5-IA
Description: All subjects will undergo written informed consent and a screening evaluation including baseline clinical laboratory testing, a baseline physical and neurological evaluation and baseline cognitive evaluations using the MMSE, the ANAM computerized cognitive battery, and other tests of executive function. All subjects will be evaluated with United Parkinson Disease Rating Scales (UPDRS) following an overnight withdrawal of anti-parkinson medication. Subjects will be asked to undergo an injection of \[123I\] 5-IA followed by SPECT imaging as described below. A second \[123I\] 5-IA and SPECT imaging study will be obtained for reliability testing between 2 weeks and 2 months following the initial \[123I\] 5IA imaging session.
Study: NCT03058640

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PKSA karate class
Description: Participants will attend at least 20/24 PKSA karate classes over a 12 week period, completing standard karate training lessons. Participants will also be encouraged to practice on their own at home.~• Participants must attend at LEAST 20/24 classes
Study: NCT01581164

Intervention type: BIOLOGICAL
Intervention: Influenza vaccine
Description: Influenza vaccine: Injection, post transplant

Intervention type: BIOLOGICAL
Intervention: Varicella vaccine
Description: Varicella vaccine: Injection, post transplant
Study: NCT01962298

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sugammadex 2mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sugammadex 2mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neostigmine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sugammadex 4mg/kg
Study: NCT02263131

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VAXIGRIP Prefilled Syringe INJ.
Description: VAXIGRIP Prefilled Syringe INJ.0.5mL or 0.25mL
Study: NCT02925325

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: Music therapy (MT) treatment focuses on the use of 2 techniques of intervention: receptive MT and active MT. The work of receptive application is described as the use of prerecorded music or executed by the music therapist with effect on the patient, without the latter's active involvement in the psychotherapeutic process of musical creation. While the active application, both the music therapist and patient are involved in musical creation, for example, the use of voice, body and musical instruments (Muñoz, 2008). Contemplate their psychotherapeutic possibilities in 3 different dimensions of patient: body, emotional and social work, as explained above. Treatment with MT, as in cognitive behavioral therapy, includes breathing exercises, stress-relaxation techniques, psychoeducation, and exercises for the management of irrational thoughts and erratic behavior patterns (Dobson and Dozois, 2010).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Treatment
Description: It is the usual medical treatment that patients with major depressive disorder in remission but with residual symptom receives at the sponsor institution in a monthly basis.
Study: NCT03624296

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI 7T
Description: MRI 7T

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEST EDSS
Description: EDSS - Expanded Disability Status Scale

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEST MSFC
Description: MSFC - Multiple Sclerosis Functional Composite
Study: NCT04108676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: PARP inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: proton pump inhibitor
Study: NCT03649867

Intervention type: OTHER
Group type: OTHER
Intervention: Semi-structured interviews
Description: Each participant will attend a 30-45 minute semi-structured interview conducted by the CI
Study: NCT03332550

Intervention type: PROCEDURE
Intervention: Laparoscopic lavage
Description: Operation with laparoscopic lavage for perforated diverticulitis Hinchey 3

Intervention type: PROCEDURE
Intervention: Colon resection
Description: Operation with colon resection for perforated diverticulitis Hinchey 4

Intervention type: PROCEDURE
Intervention: Colon resection
Description: Operation with colon resection for perforated diverticulitis Hinchey 4
Study: NCT02524210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Description: dabigatran etexilate 150 mg/day (1 day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Description: dabigatran etexilate 150 mg/day (1 day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Description: dabigatran etexilate 150 mg/day (1 day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole and Dabigatran
Description: rabeprazole 20 mg / day for 5 days, then the 6th day concomitant rabeprazole 20 mg of dabigatran etexilate 150 mg;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole and Dabigatran
Description: rabeprazole 20 mg / day for 5 days, then the 6th day concomitant rabeprazole 20 mg of dabigatran etexilate 150 mg;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole and Dabigatran
Description: rabeprazole 20 mg / day for 5 days, then the 6th day concomitant rabeprazole 20 mg of dabigatran etexilate 150 mg;
Study: NCT00678574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluoxetine
Description: Fluoxetine 20 mg daily by mouth for 2-3 months.
Study: NCT00449787

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan 100 mg
Description: Sumatriptan 100mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen 500mg tablet
Study: NCT01933516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP2013
Description: GP2013
Study: NCT03702595

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hip flexors stretching protocol
Description: Stretching protocol of rectus femoris, vastus lateralis and iliopsoas according to Kaltenborn- Evjenth Orthopaedic Manual Therapy Concept (OMT)
Study: NCT02062008

Intervention type: DEVICE
Group type: OTHER
Intervention: PET-MRI
Description: PET-MRI with intravenous Gadolinium and FDG. The entire study will take approximately one hour.
Study: NCT01901757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1201, Fasted followed by fed
Description: There are 2 administration periods with 7 days of wash-out. In period 1, the subjects will receive a single oral dose of HCP1201 under fasted condition. In period 2, the subjects will receive a single oral dose of HCP1201 under fed condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1201, Fasted followed by fed
Description: There are 2 administration periods with 7 days of wash-out. In period 1, the subjects will receive a single oral dose of HCP1201 under fasted condition. In period 2, the subjects will receive a single oral dose of HCP1201 under fed condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1201, Fed followed by fasted
Description: There are 2 administration periods with 7 days of wash-out. In period 1, the subjects will receive a single oral dose of HCP1201 under fed condition. In period 2, the subjects will receive a single oral dose of HCP1201 under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1201, Fed followed by fasted
Description: There are 2 administration periods with 7 days of wash-out. In period 1, the subjects will receive a single oral dose of HCP1201 under fed condition. In period 2, the subjects will receive a single oral dose of HCP1201 under fasted condition.
Study: NCT02156505

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: placement of double bare stent
Study: NCT02156505

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DoubleBare stent
Study: NCT01423084

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Serogroup B meningococcal vaccine
Description: All subjects will receive two rMenB+OMV NZ vaccinations one month apart and will be followed for a total of 2 months. Subjects will be randomized to 1 of 2 treatment arms to receive either two doses of rMenB+OMV NZ vaccine Lot 1 or two doses of rMenB+OMV NZ Lot 2.~A total of 2 blood samples will be collected (at the first vaccination and 1 month after the 2nd vaccination). An additional blood draw will be collected in a subset of approximately 160 subjects (approximately 80 subjects in Group 1 and approximately 80 subjects in Group 2) at 2 weeks after the second vaccination

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Serogroup B meningococcal vaccine
Description: All subjects will receive two rMenB+OMV NZ vaccinations one month apart and will be followed for a total of 2 months. Subjects will be randomized to 1 of 2 treatment arms to receive either two doses of rMenB+OMV NZ vaccine Lot 1 or two doses of rMenB+OMV NZ Lot 2.~A total of 2 blood samples will be collected (at the first vaccination and 1 month after the 2nd vaccination). An additional blood draw will be collected in a subset of approximately 160 subjects (approximately 80 subjects in Group 1 and approximately 80 subjects in Group 2) at 2 weeks after the second vaccination
Study: NCT04226105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP40081
Description: 1 ml of the GP40081 contains 100 units soluble insulin aspart/protamine-crystallised insulin aspart in the ratio 30/70. Insulin aspart 30 mix is self-administered drug by SC injection 1-3 times per day before meal intake.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NovoMix 30
Description: 1 ml of the NovoMix 30 contains 100 units soluble insulin aspart/protamine-crystallised insulin aspart in the ratio 30/70. Insulin aspart 30 mix is self-administered drug by SC injection 1-3 times per day before meal intake.